SCHEMBL1044217

SCHEMBL1044217

CCCCCCCCCCCCCCCCC(Cl)(C(=O)[O-])c1ccccc1.CCCCCCCCCCCCCCCCC(Cl)(C(=O)[O-])c1ccccc1.[Ca+2]

nearest known ligand 0.55

Known targets — ChEMBL curated mechanism

GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.44
CES1 P23141 3/20 0.44
SCN5A Q14524 3/20 0.44
SCN9A Q15858 3/20 0.44
HSP90AA1 P07900 1/20 0.44
GAA P10253 1/20 0.41
NAAA Q02083 1/20 0.40
NPC1 O15118 1/20 0.39
JAK2 O60674 1/20 0.39
RAB9A P51151 1/20 0.39
PAX8 Q06710 1/20 0.39
KIF11 P52732 1/20 0.39
EGFR P00533 1/20 0.38
CYP1A2 P05177 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27508355 0.87 SCN5A (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL1133623 0.87 SCN5A (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL10709944 0.84 OPRM1 (0.45) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL8720644 0.82 HDAC1 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21269749 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21268815 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21269197 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21269903 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21270032 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1
SCHEMBL21269530 0.81 CES2 (0.46) CES2CES1SCN5ASCN9AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991643-B1 USE OF POLYNUCLEAR PHENOLIC COMPOUNDS AS STABILISERS BASF SE (DE) 2019-10-30 EP disclosed
US-10062471-B2 Additive formulation suitable for antistatic modification and improving the electrical conductivity of inanimate organic material BASF SE (DE) 2018-08-28 US disclosed
EP-3263563-A1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS FUEL ADDITIVE OR LUBRICANT ADDITIVE BASF SE (DE) 2018-01-03 EP disclosed
EP-2649054-B1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND THEIR USE AS FUEL ADDITIVES OR LUBRICANT ADDITIVE BASF SE (DE) 2017-07-12 EP disclosed
US-9670430-B2 Synergistic mixture BASF SE (DE) 2017-06-06 US disclosed
US-9562202-B2 Synergistic mixture BASF SE (DE) 2017-02-07 US disclosed
US-9359570-B2 Polytetrahydrobenzoxazines and bistetrahydrobenzoxazines and use thereof as a fuel additive or lubricant additive BASF SE (DE) 2016-06-07 US disclosed
US-9315759-B2 Synergistic mixture BASF SE (DE) 2016-04-19 US disclosed
US-20160090541-A1 SYNERGISTIC MIXTURE BASF SE (DE) 2016-03-31 US disclosed
US-20150152349-A1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE BASF SE (DE) 2015-06-04 US disclosed
US-20120149617-A1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE BASF SE (DE) 2012-06-14 US disclosed
US-20110113678-A1 USE OF POLYNUCLEAR PHENOLIC COMPOUNDS AS STABILISERS BASF SE (DE) 2011-05-19 US disclosed
US-20110034360-A1 ALPHA-OLEFIN/ISOBUTENE DIBLOCK COPOLYMERS BASE SE (DE) 2011-02-10 US disclosed
EP-2272821-A2 Trinuclear phenolic compounds BASF SE (DE) 2011-01-12 EP disclosed
EP-2267104-A2 Use of polynuclear phenolic compounds as dispersants BASF SE (DE) 2010-12-29 EP disclosed
EP-2132284-B1 ADDITIVE FORMULATION SUITED FOR ANTI-STATIC FINISHING AND IMPROVEMENT OF THE ELECTRICAL CONDUCTIVITY OF INANIMATE ORGANIC MATERIAL BASF SE (DE) 2010-12-01 EP disclosed
US-20100210492-A1 SYNERGISTIC MIXTURE BASF SE (DE) 2010-08-19 US disclosed
US-20100072427-A1 ADDITIVE FORMULATION SUITABLE FOR ANTISTATIC MODIFICATION AND IMPROVING THE ELECTRICAL CONDUCTIVITY OF INANIMATE ORGANIC MATERIAL BASF SE (DE) 2010-03-25 US disclosed
US-20090065744-A1 USE OF POLYNUCLEAR PHENOLIC COMPOUNDS AS STABILISERS BASF SE (DE) 2009-03-12 US disclosed
US-5108631-A Method of overbasing with a hydroxy sulfonic acid copromoter THE LUBRIZOL CORPORATION (US) 1992-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090065744-A1 USE OF POLYNUCLEAR PHENOLIC COMPOUNDS AS STABILISERS TYR, COMT, AHR CES2 3911/4885CES1 4680/4885SCN5A 4269/4885
US-20120149617-A1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE ADH1A, ADH1C, H1-0 CES2 739/4885CES1 1954/4885SCN5A 1833/4885
US-20150152349-A1 POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE ADH1A, ADH1C, H1-0 CES2 739/4885CES1 1954/4885SCN5A 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.